Vax-Immune

Executive Summary

Vax-Immune, operating under the brand LabReady, is a San Diego-based private company revolutionizing infectious disease diagnostics with its MyLabReady platform. This qPCR-AI system enables rapid, lab-grade syndromic testing in decentralized settings like clinics, pharmacies, and farms. Founded in 2019, the company aims to democratize molecular diagnostics, delivering results in minutes. Its innovation lies in combining multiplex qPCR with AI interpretation, eliminating the need for traditional labs. With a focus on infection testing, Vax-Immune addresses the growing demand for point-of-care solutions to combat infectious diseases. The market opportunity is substantial as healthcare moves toward decentralized diagnostics, positioning the company for potential growth pending regulatory and commercial milestones.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CE marking for MyLabReady syndromic panel50% success
• Q2 2026Strategic partnership with major pharmacy chain for distribution40% success
• Q2 2026Series A or B funding round to support commercial launch60% success